In this study, we demonstrated USP22 as a novel driver of Sorafenib resistance in hepatocellular carcinoma, presenting a new potential therapeutic target for Sorafenib‐resistant hepatocellular carcinoma. The gene discussed is USP22; the disease is hepatocellular carcinoma.